Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
10 Results Found
Fact Sheet: The 340B Drug Pricing Program
Learn what the HHS 340B Drug Pricing Program is and what 340B hospitals are. The program allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients by providing 340B drug pricing discounts and expand health services to the patients and communities they serve.
Report highlights how 340B arrangements with community and specialty pharmacies improve access to care for underserved patients
The AHA Sept. 9 released a report highlighting how hospitals’ arrangements with community and specialty pharmacies improve access to care for underserved patients.
House Judiciary Committee to investigate CVS Caremark for potential antitrust violations
Members of the House Judiciary Committee last week announced an investigation of CVS Caremark for potential practices that could limit patient access to innovative services provided by some independent pharmacies.
AHA files brief to defend ruling in favor of Mississippi’s 340B contract pharmacy law
The AHA Nov. 15 filed friend-of-the-court briefs in the U.S. Court of Appeals for the 5th Circuit in support of an earlier denial by the U.S. District Court for the Southern District of Mississippi of preliminary injunctions sought by Novartis and PhRMA against enforcement of the state's 340B contract pharmacy law.
AHA, others file amicus brief in Maryland to prevent injunction against 340B pricing for contract pharmacy arrangements
The AHA, 340B Health, the Maryland Hospital Association and the Mid-Atlantic Association of Community Health Centers June 26 filed an amicus brief in a federal district court in Maryland, defending the state's law protecting 340B pricing for contract pharmacy arrangements.
AHA, FAH Amicus Brief in FTC Non-Compete Case
While the AHA respects the FTC’s efforts to address issues of genuine unequal bargaining power between certain employers and certain types of workers, the FTC proposed non-compete rule would profoundly transform the health care labor market – particularly for physicians and senior hospital executives.
Texas court blocks FTC non-compete ban
A Texas federal court Aug. 20 ruled set aside the Federal Trade Commission’s Non-Compete Clause Final Rule. U.S. District Judge Ada Brown held the FTC lacked the authority to enact the rule, which would ban, as an unfair method of competition, contractual terms that prohibit workers from pursuing certain employment after their contract with an employer ends.
AHA and AHIP File Joint Amicus Brief
Today, the American Hospital Association (AHA) and AHIP filed a joint amicus brief in United States v. Supervalu Inc. v. Safeway Inc. In the brief, the organizations argue that the federal government’s “erroneous construction and expansion of the FCA [False Claims Act] threatens the legitimate business activities of every government contractor, hospital, healthcare provider, health insurance provider, and grant recipient in the nation,” and would “ultimately divert resources away from the primary missions of AHA’s and AHIP’s members: caring for patients, reducing the cost of care, and ensuring a healthy citizenry.”
340B Advocacy Alliance Bulletin: Federal District Judge Issues Ruling In Eli Lilly 340B Contract Pharmacy Case
A federal district court judge in Indiana Friday agreed with the government’s contention that the 340B statute would permit the Department of Health and Human Services to require that the drug company Eli Lilly offer 340B discounts for drugs distributed by hospitals through community pharmacies, finding that this was the best reading of the what the 340B statute requires
AHA 340B Advocacy Alliance Bulletin: Supreme Court Will Take up AHA’s 340B Challenge
The Supreme Court of the United States today decided to take up AHA’s petition asking to reverse a federal appeals court decision that significantly cuts payments to certain hospitals that participate in the 340B Drug Pricing Program, threatening access to care in communities.